8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) March 9, 2020

GENETHERA, INC.

  (Exact name of Registrant as specified in its charter)

NEVADA	000-27237	65-0622463
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3051 W. 105th Ave.# 350251 Westminster, CO		80035
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (303) 955-0190

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

On March 9, 2019, GeneThera, Inc. terminated its engagement relationship with BFBorgers, CPA, PC; its former independent auditors. There were no disagreements or disputed matters between the Company and Ben Borges on any matter of accounting principles or practices, financial statement disclosures, or any matters concerning, and/or related to auditing scope or procedure.

On March 9, 2019 the Board of Directors voted to formally engage MaughanSullivan, LLC as the Company’s new independent auditors for the year ended December 31, 2019; including all quarterly reviews and audits, thereafter.

ITEM 9.01 EXHIBITS

Exhibit Number	Description
Exhibit 10.1	Dismissal Letter of BFBorgers, CPA, PC

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 9, 2020	GENETHERA, INC.
	By:	/s/ Tannya L. Irizarry
		Tannya L. Irizarry Chief Financial Officer

2

EX-10.1

March 8, 2020

Ben F Borgers

B F Borgers CPA PC

5400 W Cedar Ave

Lakewood, co 80226

We have engaged MaughanSullivan LLC to audit our financial statements for the year ended December 31, 2019. In connection with their audit, they would like to make inquiries and examine your workpapers for audit of our financial statements for the year ended December 31, 2018 and the Quarterly Reviews for the quarters ended March 31, 2018, June 30, 2018 and September 30, 2018. We authorize you to respond fully and without limitation to their inquiries.

With retention of MaughanSullivan LLC your services on our behalf will terminate as of March 9, 2020.

Please allow MaughanSullivan LLC to copy information from your files that providesfactual information about our company.

We have represented to our auditors that we are not involved with your firm in any disputes about accounting principles, auditing procedures, or similarly significant matters, and that we have paid in full for all audit services rendered by you to date. You will be contacted by Heber C. Maughan of MaughanSullivan LLC concerning these matters.

It has been a pleasure to work with you. Thank you for all of your endeavors on our behalf.

Warm regards,

/s/ Antonio Milici

Antonio Milici, MD Ph.D

Chairman and CEO